7 results about "M-anisic acid" patented technology

The invention provides recombinant escherichia coli for de novo synthesis of anisic acid. At least one of the following improvements is carried out on an escherichia coli starting strain: (1) overexpression of O-methyltransferase PSA-OMT1 from Pleuromyces sapidus, (2) overexpression of O-methyltransferase PSA-OMT1 from Pleuromyces sapidus, and (3) overexpression of O-methyltransferase PSA-OMT1 from Pleuromyces sapidus; the method comprises the following steps: carrying out overexpression on chorismate lyase UbiC derived from E.coli MG1655 or Providencia rustiana, and carrying out the overexpression on the chorismate lyase UbiC derived from E.coli MG1655 or Providencia rustiana; (2) carrying out overexpression on a 3-deoxy-D-arabic-heptanone acid 7-phosphate (DAHP) synthase feedback inhibition mutant AroGD146N derived from E.coli MG1655 on the basis of the step (1); and (3) overexpressing synthase PpsA derived from phosphoenolpyruvate (PEP) on the basis of the step (2), and knocking out a pykF gene for coding pyruvate kinase I. Therefore, in the fermentation process of the recombinant escherichia coli, the accumulation of the anisic acid in the fermentation liquor can be realized, the maximum anisic acid shake flask yield of the recombinant escherichia coli can reach 284.9 mg / L, and a foundation is laid for the subsequent construction of high-yield anisic acid engineering bacteria.

The present invention relates to an antimicrobial composition applicable to a powder formulation, the antimicrobial composition containing a combination of caprylyl glycol, ethylhexylglycerin, and p-anisic acid, or a combination of 1,3-propanediol, methylpropanediol, and p-anisic acid. Due to containing a combination of specific components, when the antibacterial composition is applied to a powder formulation, the antibacterial composition exhibits appropriate antiseptic properties even at a low content, and the powder formulation has excellent stability because mold mycelium or moisture condensation is prevented from occurring even in a high humidity environment.

The invention relates to a preparation method and application of a temperature-controlled gene expression nanomaterial, which can effectively solve the problem of avoiding damage to transfected cells and surrounding tissues caused by excessive heat through precise temperature control and realizing non-destructive photothermal activation of genetic engineering. The preparation method is as follows: chitosan is dissolved in an acetic acid deionized water solution to prepare a solution A; EDC and p-anisic acid are added to DCM, NHS is added, stirred under argon at room temperature, dried, and then thiol-polyethylene glycol-carboxyl is added to react under N2 protection to synthesize AEAA-PEG-COOH; NHS and EDC are added to the solution A, stirred for 1 hour, and then AEAA-PEG-COOH is added, stirred overnight, dialyzed, and freeze-dried to obtain a powder B; a mixture of thermosensitive green, beta-naphthol and polyethylene glycol is infrared-heated and dissolved in acetone to obtain a solution C; the solution C is dripped into the powder B, stirred evenly, centrifuged, and impurities are removed to obtain a nanomaterial D; the thermosensitive green in the nanomaterial D is reacted with a plasmid, centrifuged, and the unadsorbed plasmid is removed to obtain the temperature-controlled gene expression nanomaterial.

The present invention generally relates to a formulation comprising at least two of compounds A, B and C, (A) maltol, (B) anisic acid, (C) an alkanediol, as well as at least one of, components D, E, and F, (D) an emulsifier, (E) an oil component, and (F) a water component.

The invention relates to cosmetic and dermatological preparations comprising a combination of levulinic acid and anisic acid. The preparations according to the invention are particularly suitable for application to the skin. These preparations exhibit selective antibacterial action on the skin, specifically targeting anaerobic bacteria of the skin flora, while having little or no bactericidal action against aerobic bacteria. The compositions according to the invention are therefore suitable for cosmetic skin care as well as for the dermatological treatment of certain skin conditions, such as acne.

The present invention provides a recombinant Escherichia coli for synthesizing anisic acid from scratch, wherein at least one of the following improvements is made to the starting strain of Escherichia coli: (1) overexpressing O-methyltransferase PSA-OMT1 from Pleurotus sapidus; overexpressing chorismate lyase UbiC from E. coli MG1655 or Providencia rustigianii; (2) overexpressing a feedback inhibition mutant AroG of 3-deoxy-D-arabino-heptanoic acid 7-phosphate (DAHP) synthase from E. coli MG1655 on the basis of (1); D146N (3) Based on (2), the enzyme PpsA derived from phosphoenolpyruvate (PEP) synthase was overexpressed, and the pykF gene encoding pyruvate kinase I was knocked out. Thus, the recombinant E. coli of the present invention can achieve accumulation of anisic acid in the fermentation broth during the fermentation process, and the maximum anisic acid yield of the recombinant E. coli in a shake flask can reach 284.9 mg / L, laying the foundation for the subsequent construction of high-yield anisic acid engineered bacteria.

The present invention generally relates to a formulation comprising at least two of compounds A, B and C, (A) maltol, (B) anisic acid, (C) an alkanediol, as well as at least one of, components D, E, and F, (D) an emulsifier, (E) an oil component, and (F) a water component.